Navigation Links
Synergy Pharmaceuticals, Inc. Files Suit Against Ironwood Pharmaceuticals, Inc. and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie
Date:12/13/2011

NEW YORK, Dec. 13, 2011 /PRNewswire/ -- Synergy Pharmaceuticals, Inc. (Nasdaq: SGYPD, SGYPU), a developer of new drugs to treat gastrointestinal (GI) disorders and diseases, announced today that it has filed a lawsuit in New York State Supreme Court against Ironwood Pharmaceuticals, Inc. (Nasdaq: IRWD) and its Chief Scientific Officer and Senior VP of R&D, Dr. Mark G. Currie. 

The lawsuit alleges that after European patent 1,379,224 was granted to Synergy but prior to issuance, Ironwood and Dr. Currie opposed the patent before the European Patent Office and presented to the European Patent Office and the United States Patent and Trademark Office, data and arguments that were false, contradictory, inaccurate and misleading.  In its complaint, Synergy accuses Ironwood and Dr. Currie of, among other things, unfair competition, fraud and unjust enrichment and seeks $500 million in actual and punitive damages.

About Synergy Pharmaceuticals, Inc.

Synergy is a biopharmaceutical company focused on the development of new drugs to treat gastrointestinal disorders and diseases. Synergy's proprietary drug candidate plecanatide is a synthetic analog of the human gastrointestinal hormone uroguanylin, and functions by activating the guanylate cyclase C receptor on epithelial cells of the GI tract. Synergy completed a Phase I study of plecanatide in healthy volunteers and a Phase IIa clinical trial in patients to treat chronic idiopathic constipation (CIC) patients. In October 2011, Synergy initiated dosing of patients in a major Phase II/III clinical trial of plecanatide in CIC patients. Plecanatide is also being developed to treat constipation-predominant irritable bowel syndrome, with the first trial in IBS-C patients planned for 2012. Synergy's second GC-C agonist SP-333 is currently in pre-clinical development to treat inflammatory bowel diseases. More information is available at http://www.synergypharma.com.  


'/>"/>
SOURCE Synergy Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Related biology technology :

1. Synergy Business Solutions Acquires the Microsoft Dynamics SL Practice of Congruent Software, Inc.
2. Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT
3. VioQuest Pharmaceuticals, Inc Q2/08 Review Issued by Scimitar Equity, LLC
4. Rib-X Pharmaceuticals, Inc. Announces Formation of Clinical Advisory Board
5. Pacira Pharmaceuticals, Inc. Adds Experienced Physician Dr. David St. Peter to Leadership Team
6. Transcept Pharmaceuticals, Inc. to Present at the Natixis Bleichroeder Second Annual Hidden Gems Conference
7. Transdel Pharmaceuticals, Inc. Retains The Investor Relations Group
8. Chemical Engineering Conference Highlights Energy, Biomedicine, Pharmaceuticals, Sustainability and Centennial
9. Alseres Pharmaceuticals, Inc. Reports Third Quarter 2008 Operational and Financial Results
10. Johnson & Johnson Completes Acquisition of Omrix Biopharmaceuticals, Inc.
11. Alseres Pharmaceuticals, Inc. Announces $1 Million Financing
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/15/2020)... ... 2020 , ... This new service offers clients a way to speak with ... as the need arises. Lachman’s OnCall SMEs have extensive knowledge of a wide range ... Lachman OnCall™ SMEs are available normal business hours Monday through Friday from 9:00 am ...
(Date:5/14/2020)... ... May 13, 2020 , ... Early stages of drug discovery ... no information on the drug’s mechanism of action (MOA). Gene expression profiling technologies ... the activity of molecular pathways. This information can complement phenotypic readouts and can ...
(Date:5/1/2020)... NEW YORK (PRWEB) , ... April 30, 2020 ... ... Ideas Awards were announced today, honoring the businesses, policies, projects, and concepts that ... is a revolutionary bioprinter for living cells, which has taken out the top ...
(Date:4/22/2020)... Mich. (PRWEB) , ... April 21, 2020 , ... ... researchers continue their work through COVID-19. Many clinical trial teams are working remotely ... online. Ripple Science wants to help researchers continue their research during this uncertain ...
Breaking Biology Technology:
(Date:5/14/2020)... ... May 12, 2020 , ... Akara ... and easily project contracted liabilities with payers, providers and pharmacies – now ... to Commercial and Government entities, Copay and Patient Assistance Program liabilities and ...
(Date:5/14/2020)... ... May 14, 2020 , ... The ... sales representatives, found the 2019 average medical sales rep total compensation increased by ... by uncertainties amid the COVID-19 global crisis. , The MedReps 2020 Salary Survey ...
(Date:5/6/2020)... Mass. (PRWEB) , ... May 06, 2020 , ... ... a privately held medical technology company dedicated to improving the quality, safety, efficacy and ... partnership that will help SCDAA deliver on its mission and meet its goals. In ...
Breaking Biology News(10 mins):